Literature DB >> 6542302

The role of abnormal vitamin D metabolism in X-linked hypophosphatemic rickets and osteomalacia.

M K Drezner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542302     DOI: 10.1007/978-1-4684-4808-5_48

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  6 in total

Review 1.  The molecular background to hypophosphataemic rickets.

Authors:  P S Rowe
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.

Authors:  Peter S N Rowe; Naoko Matsumoto; Oak D Jo; Remi N J Shih; Jeannine Oconnor; Martine P Roudier; Steve Bain; Shiguang Liu; Jody Harrison; Norimoto Yanagawa
Journal:  Bone       Date:  2006-06-09       Impact factor: 4.398

3.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

4.  Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets.

Authors:  H S Tenenhouse; G Jones
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

5.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

6.  Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.

Authors:  Theresa Berndt; Theodore A Craig; Ann E Bowe; John Vassiliadis; David Reczek; Richard Finnegan; Suzanne M Jan De Beur; Susan C Schiavi; Rajiv Kumar
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.